awmsg logo

eculizumab (Soliris®)

Reference No. 1153

Publication date:

Appraisal information

eculizumab (Soliris®) 300 mg concentrate for solution for infusion

Company: Alexion Pharma UK Ltd
BNF category: Nutrition and blood
NMG meeting date: Not scheduled
AWMSG meeting date: 11/02/2015
Submission Type: NICE HST
Status: Recommended
Advice No: Not available
Ratification by Welsh Government: 12/08/2015

Current Progress

Ratification by
Welsh Government

AWMSG advice

The National Institute for Health and Care Excellence (NICE) published advice in January 2015 in relation to eculizumab (Soliris®) for the treatment of patients with atypical haemolytic uraemic syndrome (aHUS). At their meeting on 11th February 2015 AWMSG supported the adoption and implementation of this advice within NHS Wales (refer to the minutes of meetings). The Minister for Health and Social Services has subsequently agreed that the NICE HST advice for eculizumab (Soliris®) should be implemented within NHS Wales. A National Clinical Access Policy will be developed by Welsh Health Specialised Services Committee (WHSSC) with the support of clinical experts, patient representatives and other key stakeholders. Refer to the NICE website for full guidance including any specific restrictions on the use of the technology.